Clinical Consultations™

Clinical Consultations™: Closing the Gap in Early Identification and Treatment of SMA

Advances In&trade;

Advances In™ Amyotrophic Lateral Sclerosis &mdash; Developments in SOD1 Targeting

Clinical Consultations: An Expert Discussion on Immunoglobulin Therapy in CIDP &mdash; Optimizing Treatment to Improve Quality of Life

Enduring Activity

3rd Annual Advanced Practice Collaborative

Community Practice Connections™

Community Practice Connections™: 2nd Annual International Congress on the Future of Neurology®

Burst CME

Burst CME™ – Optimizing Care of Parkinson's Disease: Part 1

Burst CME™ – Optimizing Care of Parkinson's Disease: Part 2

Updates in the Journey for Disease-Modifying Therapies for Alzheimer Disease

Online Case Investigations: Multidisciplinary Evaluations of Acute Hepatic Porphyria - How Can We Improve Recognition and Treatment?

Advances in™ Diagnosis, Multidisciplinary Management, and Optimal Treatment of Amyotrophic Lateral Sclerosis

BURST CME™ in ALS: Streamlining the Pathway From Research to Treatment

Patient & Provider Connection: A Patient's Journey Living With Narcolepsy

<h2 style="text-align:center">Advances in Acute Treatment of Acquired Thrombotic Thrombocytopenic Purpura</h2>

On-Demand 1.0 hour Accredited Webcast

<div style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px; text-align:center">This activity is supported by an educational grant from 
Sanofi Genzyme.</div>
 
Faculty Presenter 
 
Kathryn E. Dane, PharmD, BCPS 
Clinical Pharmacist, Benign Hematology and Cardiology 
Co-director, Hemostatic and Antithrombotic Stewardship Program 
The Johns Hopkins Hospital 
Baltimore, Maryland 
&nbsp;
<div>
<hr /></div>
 
Program Description 
Thrombotic thrombocytopenic purpura (TTP) is a rare, life-threatening thrombotic microangiopathy, requiring prompt diagnosis and treatment. The majority of TTP cases are acquired, resulting from a deficiency in ADAMTS13. The historic treatment has consisted of corticosteroids and plasma exchange, with newer therapies including immunosuppression and agents that modify the interaction between von Willebrand factor and platelets. This activity will review the pathophysiology and diagnosis of TTP, with a focus on available treatments. Additionally, the role of the pharmacist in managing this patient population will be emphasized, with a review of counseling pearls and adherence strategies. 
 
Target Audience:&nbsp;Health-system, oncology, and specialty pharmacists 
Type of Activity:&nbsp;Application 
Release date: July 28, 2021 
Expiration date: July 28, 2022 
Time to complete activity: 1.0 hour 
Fee: Free 
 
Educational Objectives 
At the completion of this activity, participants will be able to:
<ul>
	<li>Examine the prevalence, pathophysiology, screening, and accurate diagnosis of acquired thrombotic thrombocytopenic purpura (aTTP)</li>
	<li>Analyze efficacy and safety data for current treatment options for aTTP</li>
	<li>Identify the role of specialty and health-system pharmacists in an interdisciplinary team to maximize outcomes for patients with aTTP</li>
</ul>
 
<img alt="acpe" src="https://ptce.s3.amazonaws.com/_media/_eblast/ACPE_Large.jpg" style="float:left; height:59px; width:60px" />Pharmacy Times&nbsp;Continuing Education&trade; is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-21-287-H01-P. The activity is available for CE credit through July 28, 2022. 
 
 
Instructions for Completing the Activity and Receiving CPE Credit 
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date. 
&nbsp;
<hr /> 
Disclosures 
 
Kathryn E. Dane, PharmD, BCPS, has the following relevant financial relationships with commercial interests to disclose: 
 
Past honorarium from Alexion Pharmaceuticals Inc., Biomarin Pharmaceuticals, and Janssen Pharmaceuticals. 
 
Pharmacy Times&nbsp;Continuing Education&trade;&nbsp;Planning Staff&nbsp;&ndash; Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Meg Taylor, PharmD, CPP; Liz Rauh; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose. 
 
An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose. 
 
Educational Disclaimer 
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources. 
 
For questions about this internet CPE activity, please contact: 
<a href="mailto:ceinfo@pharmacytimes.com">ceinfo@pharmacytimes.com</a> 
Privacy Policy and Terms of Use Information: 
<a href="http://www.pharmacytimes.org/terms">www.pharmacytimes.org/terms</a> 
&nbsp;

Advances in Acute Treatment of Acquired Thrombotic Thrombocytopenic Purpura 

<h2 style="text-align:center">The Evolving Treatment Paradigm for the Management of CIDP: Opportunities for Pharmacists to Optimize Care</h2>

Live Free Accredited Virtual Panel Discussion! 
August 19, 2021 - 8:00 PM ET

<div style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px; text-align:center">This activity is supported by an educational grant from 
CSL Behring.</div>
 
Moderator 
 
Erica Marini, PharmD, MS, BCPS 
Clinical Pharmacist, Neurology 
University of Utah Health 
Salt Lake City, Utah 
 
Faculty Presenters 
 
Jeffrey Allen, MD 
Associate Professor 
Department of Neurology 
Division of Neuromuscular Medicine 
University of Minnesota 
Minneapolis, Minnesota 
 
Amy Clarke, BSN, RN, IgCN 
National Director, Clinical Practice 
Optum Infusion Pharmacy 
Lenexa, Kansas 
 
Leslie Myers, RPh, PharmD, IgCP 
Clinical Pharmacist 
Specialty and Infusion Services 
Optum Infusion Pharmacy 
Raleigh, North Carolina 
 
Medical Writers for Panel Discussion 
 
Brittany Hoffmann-Eubanks, PharmD, MBA 
Founder and CEO 
Banner Medical LLC 
Frankfort, Illinois 
 
Miriam A. Opara, PharmD 
Medical Writer 
Banner Medical LLC 
Frankfort, Illinois 
 
Medical Writer for Whiteboarding Videos 
 
Brittany Hoffmann-Eubanks, PharmD, MBA 
Founder and CEO 
Banner Medical LLC 
Frankfort, Illinois 
&nbsp;
<div>
<hr /></div>
 
Program Description 
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare, acquired, autoimmune neuropathy affecting the central nervous system and is often a disabling condition, with one-third of patients progressing to wheelchair dependence. Although disease-related disability is common, approximately 30% of patients achieve cure or remission with treatment. Current treatment strategies include corticosteroids, intravenous or subcutaneous immune globulin therapy, therapeutic plasma exchange, and supportive care, which allow for improvement in symptoms and functional status. Specialty and infusion pharmacists should be aware of the tremendous impact a diagnosis of CIDP may have for patients and their caregivers. They are well positioned to collaborate with the multidisciplinary team to individualize therapy to help patients achieve treatment goals. The expert panelists will raise awareness of CIDP and engage in a detailed discussion of the nuances of available therapies. 
 
Target audience:&nbsp;Specialty pharmacists 
Type of activity:&nbsp;Application 
Fee: Free 
 
Educational Objectives 
At the completion of this activity, participants will be able to:
<ul>
	<li>Examine the pathophysiology, clinical presentation, and burden of chronic inflammatory demyelinating polyneuropathy (CIDP)</li>
	<li>Document the current efficacy and safety data, dosing, and administration of therapies for CIDP</li>
	<li>Identify the role of the pharmacist in improving patient outcomes in CIDP by recognizing risk factors and providing patient counseling, monitoring therapy, and addressing challenges</li>
</ul>
 
<img alt="acpe" src="https://ptce.s3.amazonaws.com/_media/_eblast/ACPE_Large.jpg" style="float:left; height:59px; width:60px" />&nbsp;Pharmacy Times&nbsp;Continuing Education&trade; is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-21-275-L01-P. The activity is available for CE credit through October 19, 2021. 
 
 
Instructions for Completing the Activity and Receiving CPE Credit 
To receive CPE credit, participants must complete the pretest, view the webinar in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date. 
&nbsp;
<hr /> 
Disclosures 
 
Faculty 
Erica Marini, PharmD, MS, BCPS, Amy Clarke, BSN, RN, IgCN, and Leslie Myers, RPh, PharmD, IgCP, have no relevant financial relationships with commercial interests to disclose. 
 
Jeffrey Allen, MD, has the following relevant financial relationships with commercial interests to disclose:

<ul>
	<li>Consultant: Alexion, Argenx, Akcea, CSL Behring, Takeda, Grifols</li>
	<li>Speakers Bureau: Akcea, CSL Behring</li>
</ul>
 
Medical Writing and Editorial Support 
Brittany Hoffmann-Eubanks, PharmD, MBA, and Miriam A. Opara, PharmD,&nbsp;have no relevant financial relationships with commercial interests to disclose. 
 
Pharmacy Times&nbsp;Continuing Education&trade;&nbsp;Planning Staff&nbsp;&ndash; Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Rose Namissa, PharmD, BCPS; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose. 
 
Anonymous peer reviewers are used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose. 
 
Activity Disclaimer 
Pharmacy Times&nbsp;Continuing Education&trade; (PTCE) strives to provide the highest level of service. However, unforeseen circumstances may necessitate the rescheduling or cancellation of live events, including, but not limited to, webinars hosted by PTCE. PTCE reserves the right to cancel an event without notice. PTCE will not be responsible for any expenditure incurred due to the cancellation. 
 
Educational Disclaimer 
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources. 
 
For questions about this live CPE activity, please contact: 
<a href="mailto:ceinfo@pharmacytimes.com">ceinfo@pharmacytimes.com</a> 
Privacy Policy and Terms of Use Information: 
<a href="http://www.pharmacytimes.org/terms">www.pharmacytimes.org/terms</a> 
&nbsp;

The Evolving Treatment Paradigm for the Management of CIDP: Opportunities for Pharmacists to Optimize Care

<h2 style="text-align:center">Treatment Interventions for Dementia-Related Psychosis: Current and Future Strategies to Reduce Healthcare Spending</h2>

On-Demand Accredited Online Article

<div style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px; text-align:center">This activity is supported by an educational grant from 
Acadia Pharmaceuticals Inc.</div>
 
Faculty 
 
Megan Maroney, PharmD, BCPP 
Clinical Associate Professor 
Ernest Mario School of Pharmacy at Rutgers 
The State University of New Jersey 
Piscataway, New Jersey 
&nbsp;
<div>
<hr /></div>
 
Program Description 
Care for older adult patients with dementia-related psychosis can be costly, with total global economic cost increasing from $279.6 billion in 2000 to $948 billion in 2016. Much of the cost of care for these patients is related to nursing home stays and hospitalizations, though many personnel in these care settings lack adequate training for addressing agitation, aggression, or the delusions and hallucinations associated with dementia-related psychosis. Current guideline recommendations gives preference to nonpharmaceutical interventions, with antipsychotics reserved for use with patients experiencing severe symptoms. Accountable care organizations must take on the responsibility of providing their specialists with adequate behavioral and mental healthcare training, especially for patients presenting with dementia-related psychosis, as it may reduce use of healthcare services throughout the system. Antipsychotic indication restrictions, regulations, and billing requirements can also financially impact the institution caring for the patient. The clinical and economic data presented in this activity can be incorporated into quality initiatives to reduce healthcare spending and improve institution-based management strategies for patients with behavioral and mental health conditions, such as dementia-related psychosis. 
 
Target audience:&nbsp;Managed care pharmacists 
Type of activity:&nbsp;Application 
Release date: June 30, 2021 
Expiration date: July 15, 2022 
Time to complete activity: 2.0 hours 
Fee: Free 
 
Educational Objectives 
At the completion of this activity, participants will be able to:
<ul>
	<li>Explain the clinical presentation of dementia and the high rate of psychosis in this population as well as its effect on patients and institution-based caregivers.</li>
	<li>Examine off-label use of first- and second-generation antipsychotic medications for dementia-related psychosis.</li>
	<li>Analyze factors driving cost of care as well as economic spending data for existing and new classes of drug therapy for dementia-related psychosis.</li>
	<li>Investigate strategies to reduce inappropriate spending associated with dementia-related psychosis treatment.</li>
</ul>
 
<img alt="acpe" src="https://ptce.s3.amazonaws.com/_media/_eblast/ACPE_Large.jpg" style="float:left; height:59px; width:60px" />&nbsp;Pharmacy Times&nbsp;Continuing Education&trade; is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.20 CEU) under the ACPE universal activity number 0290-0000-21-239-H01-P. The activity is available for CE credit through July 15, 2022. 
 
 
Instructions for Completing the Activity and Receiving CPE Credit 
To receive CPE credit, participants must complete the pretest, read the article in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date. 
&nbsp;
<hr /> 
Disclosures 
 
Megan Maroney, PharmD, BCPP, has the following relevant financial relationships with commercial interests to disclose: 
Consultant: Novus Medical Education 
Speakers Bureau: Otsuka Pharmaceuticals 
Grant/research Support: CPNP Foundation Defining the Future 
 
Pharmacy Times&nbsp;Continuing Education&trade;&nbsp;Planning Staff&nbsp;&ndash; Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose. 
 
Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose. 
 
Educational Disclaimer 
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources. 
 
For questions about this internet CPE activity, please contact: 
<a href="mailto:ceinfo@pharmacytimes.com">ceinfo@pharmacytimes.com</a> 
Privacy Policy and Terms of Use Information: 
<a href="http://www.pharmacytimes.org/terms">www.pharmacytimes.org/terms</a> 
&nbsp;

Treatment Interventions for Dementia-Related Psychosis: Current and Future Strategies to Reduce Healthcare Spending

<h2 style="text-align:center">Addressing Unmet Needs in the Treatment of Schizophrenia: The Role of the Pharmacist</h2>

On-Demand Accredited Online Article

<div style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px; text-align:center">This activity is supported by an educational grant from 
Alkermes, Inc</div>
 
Faculty 
 
Lindsey Miller, PharmD, BCPP 
Associate Professor, Pharmacy Practice 
Lipscomb University College of Pharmacy and Health Sciences 
 
Clinical Pharmacist 
Vanderbilt Psychiatric Hospital 
Nashville, TN 
 
Medical Writer for Video Vignette Scripts 
 
Amy Moll, PharmD, CCP, RPh 
Consultant Pharmacist 
The Rasa Group 
Ringwood, NJ 
 
Staff Pharmacist 
Walgreens 
Brick, NJ 
&nbsp;
<div>
<hr /></div>
 
Program Description 
Schizophrenia is a chronic mental disorder characterized by a variety of symptoms that negatively affect patients&rsquo; mental and emotional behavior. Current treatment options include first- and second-generation antipsychotics that primarily target positive symptoms of disease through dopamine modulation, but treatment challenges persist. At present, available therapies for schizophrenia have limited efficacy and are associated with a multitude of adverse effects, particularly related to movement disorders and cardiometabolic dysregulation. These issues indicate a need for agents with new mechanisms of action to address patients&rsquo; negative symptoms and cognitive symptoms of schizophrenia in addition to positive symptoms. With their knowledge of available antipsychotics, pharmacists should be equipped to use information on efficacy, safety, dosing, and administration to provide solutions for patients and caregivers and address treatment challenges. This activity will review the updated clinical practice guidelines in schizophrenia, offering guidance on patient assessment, pharmacologic treatment, and psychosocial support. 
 
Please <a href="https://players.brightcove.net/10203567001/experience_60c8d31bb0df0b0022f4c05f/share.html">click here</a> to view patient counseling video vignettes. 
 
Target Audience: Retail pharmacists 
Type of Activity:&nbsp;Application 
Release date: June 15, 2021 
Expiration date: June 15, 2022 
Time to complete activity: 2.0 hours 
Fee: Free 
 
Educational Objectives 
At the completion of this activity, participants will be able to:
<ul>
	<li>Classify the epidemiology, etiology, pathophysiology, clinical impact, and treatment challenges associated with schizophrenia</li>
	<li>Examine clinical practice guidelines for the treatment of schizophrenia, including the potential role of new and emerging therapies in the therapeutic landscape</li>
	<li>Illustrate the role of the pharmacist in optimizing care for patients with schizophrenia</li>
</ul>
 
<img alt="acpe" src="https://ptce.s3.amazonaws.com/_media/_eblast/ACPE_Large.jpg" style="float:left; height:59px; width:60px" />Pharmacy Times&nbsp;Continuing Education&trade; is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.20 CEU) under the ACPE universal activity number 0290-0000-21-213-H01-P. The activity is available for CE credit through June 15, 2022. 
 
 
Instructions for Completing the Activity and Receiving CPE Credit 
To receive CPE credit, participants must complete the pretest, read the article in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date. 
&nbsp;
<hr /> 
Disclosures 
 
The following contributors have no relevant financial relationships with commercial interests to disclose: 
 
Faculty 
Lindsey Miller, PharmD, BCPP 
 
Medical Writer 
Amy Moll, PharmD, CCP, RPh 
 
Pharmacy Times&nbsp;Continuing Education&trade;&nbsp;Planning Staff&nbsp;&ndash; Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Liz Rauh; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose. 
 
An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose. 
 
Educational Disclaimer 
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources. 
 
For questions about this internet CPE activity, please contact: 
<a href="mailto:ceinfo@pharmacytimes.com">ceinfo@pharmacytimes.com</a> 
Privacy Policy and Terms of Use Information: 
<a href="http://www.pharmacytimes.org/terms">www.pharmacytimes.org/terms</a> 
&nbsp;

Addressing Unmet Needs in the Treatment of Schizophrenia: The Role of the Pharmacist

<h2 style="text-align:center">Advances in Migraine Treatment: What the Pharmacist Needs to Know</h2>

1.5 hour On-Demand Accredited Multidisciplinary Panel Discussion!

<div style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px; text-align:center">This activity is supported by educational funding provided by 
Amgen.</div>
 
Moderator 
 
Paul G. Mathew, MD, DNBPAS, FAAN, FAHS 
Assistant Professor of Neurology 
Harvard Medical School 
Boston, Massachusetts 
 
Headache/Sports Neurology/Concussion Specialist 
Mass General Brigham Health 
Harvard Vanguard Medical Specialists 
Boston, Massachusetts 
 
Faculty Panel 
 
Jacquelyn L. Bainbridge, PharmD, FCCP, MSCS, FAES 
Professor, Clinical Pharmacy and Department of Neurology 
Skaggs School of Pharmacy and Pharmaceutical Sciences 
University of Colorado, Anschutz Medical Campus 
Aurora, Colorado 
 
Nikki Hahn, PharmD, BCACP 
Clinical Pharmacy Specialist, Neurology 
Kaiser Permanente Colorado 
Denver, Colorado 
 
P. Christopher H. Gottschalk, MD FAHS 
President 
Alliance for Headache Disorders Advocacy (AHDA) 
 
Director, Headache Medicine 
Chief, Section of General Neurology 
Yale University 
New Haven, Connecticut 
 
Medical Writing Support 
 
C. Andrew Kistler, MD, PharmD 
Clinical Instructor 
Division of Gastroenterology and Hepatology 
Thomas Jefferson University 
Philadelphia, Pennsylvania 
 
Ammie J. Patel, PharmD, BCACP 
Clinical Assistant Professor 
Department of Pharmacy Practice and Administration 
Ernest Mario School of Pharmacy 
Rutgers University 
Piscataway, New Jersey 
 
Ambulatory Care Clinical Pharmacy Specialist 
RWJBarnabas Health 
West Orange, New Jersey 
&nbsp;
<div>
<hr /></div>
 
Program Description 
Migraine has a significant and debilitating impact on patients&rsquo; physical, social, and occupational functioning. However, the limitations of current migraine therapy often lead to medication overuse. New and emerging therapies for acute and preventive migraine treatment have led to opportunities for pharmacists to intervene in patient care, change disease trajectory, and prevent medication overuse. Community pharmacists can assist in managing both acute and chronic migraines by improving patient understanding of medications and optimizing treatment paradigms to substantially reduce the burden of disease. Due to their accessibility and frequent communication with patients, community pharmacists are in a unique position to improve outcomes of patients with migraine. The interdisciplinary panelists will lead a discussion focused on challenges in individualizing treatment for patients with migraine. 
 
Target audience:&nbsp;Managed care, community, and specialty pharmacists 
Type of activity:&nbsp;Application 
Release date: June 4, 2021 
Expiration date: June 4, 2022 
Time to complete activity: 1.5 hours 
Fee: Free 
 
Educational Objectives 
At the completion of this activity, participants will be able to:
<ul>
	<li>Explore pathophysiology, incidence, and treatment challenges associated with migraine</li>
	<li>Examine the safety and efficacy of new and emerging acute and preventive therapies for migraine</li>
	<li>Identify the role of the pharmacist in recognizing medication overuse and counseling the patient about the most up-to-date migraine treatment options to individualize and improve patient care</li>
</ul>
 
<img alt="acpe" src="https://ptce.s3.amazonaws.com/_media/_eblast/ACPE_Large.jpg" style="float:left; height:59px; width:60px" />&nbsp;Pharmacy Times&nbsp;Continuing Education&trade; is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hour (0.15 CEU) under the ACPE universal activity number 0290-0000-21-241-H01-P. The activity is available for CE credit through June 4, 2022. 
 
 
Instructions for Completing the Activity and Receiving CPE Credit 
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date. 
&nbsp;
<hr /> 
Disclosures 
 
Paul G. Mathew, MD, DNBPAS, FAAN, FAHS, has the following relevant financial relationships with commercial interests to disclose: 
&nbsp;
<ul>
	<li>Consultant: Amgen, Allergan, BioHaven, Lilly, Revance, Satsuma, Supernus, Takeda, Theranica</li>
</ul>
 
The following contributors have no relevant financial relationships with commercial interests to disclose: 
 
Faculty 
Jacquelyn L. Bainbridge, PharmD, FCCP, MSCS, FAES 
Nikki Hahn, PharmD, BCACP 
P. Christopher H. Gottschalk, MD FAHS 
 
Medical Writing Support 
C. Andrew Kistler, MD, PharmD 
Ammie J. Patel, PharmD, BCACP 
 
Pharmacy Times&nbsp;Continuing Education&trade;&nbsp;Planning Staff&nbsp;&ndash; Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Dipti Desai, PharmD, CHCP; Michelle Carlson, PharmD; Kelly McCormick; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose. 
 
Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose. 
 
Educational Disclaimer 
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources. 
 
For questions about this internet CPE activity, please contact: 
<a href="mailto:ceinfo@pharmacytimes.com">ceinfo@pharmacytimes.com</a> 
Privacy Policy and Terms of Use Information: 
<a href="http://www.pharmacytimes.org/terms">www.pharmacytimes.org/terms</a> 
&nbsp;

Advances in Migraine Treatment: What the Pharmacist Needs to Know

<h2 style="text-align:center">Managing Multiple Sclerosis: Examining Oral Treatment Options and Specialty Pharmacy Considerations&nbsp;</h2>

On-Demand 1.5-hour Accredited Webcast

<div style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px; text-align:center">This activity is supported by educational grants from 
EMD Serono and Bristol Myers Squibb.</div>
 
Faculty Presenters 
 
Aimee M. Banks, PharmD, BCPS, MSCS 
Clinical Pharmacist, Multiple Sclerosis 
Vanderbilt University Medical Center 
Nashville, Tennessee 
 
Amanda Hickman, PharmD, MPH, MSCS 
Central Support Neurology Pharmacist 
Clinical Oversight Neurology Subcommittee Chair 
TrellisRx 
Atlanta, Georgia 
&nbsp;
<div>
<hr /></div>
 
Program Description 
Nearly 1 million individuals are living with multiple sclerosis (MS) in the United States. Research has shown that a wide variety of conditions have been mistaken for MS and generally result from misinterpretation of nonspecific symptoms, neurological signs, or MRI findings in common disorders. Because MS is an incurable disease, pharmacists and clinicians must recognize clinical presentation and symptoms early to initiate therapy, such as oral disease-modifying therapies (DMTs), that can help manage exacerbations, reduce relapse rates, and slow disability progression in patients with MS. DMTs and other treatment options have changed the treatment landscape of MS significantly over the past few years, and specialty pharmacists need to stay up-to-date on the latest efficacy and safety data of novel oral treatments for MS to optimize drug therapy. Specialty pharmacists also have important roles in facilitating patient access to these medications as well as selecting a patient-centered treatment regimen and promoting adherence. Informed clinical decision making and implementation of improved therapeutic approaches within the health system to manage patients with MS will ultimately improve their health-related quality of life. 
 
Target Audience:&nbsp;Managed care and specialty pharmacists 
Type of Activity:&nbsp;Application 
Release date: May 18, 2021 
Expiration date: May 18, 2022 
Time to complete activity: 1.5 hours 
Fee: Free 
 
Educational Objectives 
At the completion of this activity, participants will be able to:
<ul>
	<li>Classify the clinical presentation, diagnostic criteria, and differential diagnosis recommendations for multiple sclerosis (MS)</li>
	<li>Analyze the latest data on the efficacy, safety, and administration of oral disease-modifying therapies (DMTs) for the treatment of MS</li>
	<li>Examine the role of pharmacists in the management of MS, including identifying adherence strategies, patient counseling and improving quality of life</li>
</ul>
 
<img alt="acpe" src="https://ptce.s3.amazonaws.com/_media/_eblast/ACPE_Large.jpg" style="float:left; height:59px; width:60px" />Pharmacy Times&nbsp;Continuing Education&trade; is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-21-211-H01-P. The activity is available for CE credit through May 18, 2022. 
 
 
Instructions for Completing the Activity and Receiving CPE Credit 
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date. 
&nbsp;
<hr /> 
Disclosures 
 
Aimee M. Banks, PharmD, BCPS, MSCS, has the following relevant financial relationships with commercial interests to disclose:

<ul>
	<li>Advisory Board Consultant: EMD Serono</li>
</ul>
 
Amanda Hickman, PharmD, MPH, MSCS, has no relevant financial relationships with commercial interests to disclose. 
 
Pharmacy Times&nbsp;Continuing Education&trade;&nbsp;Planning Staff&nbsp;&ndash; Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Rose Namissa, PharmD, BCPS; Michelle C. Carlson, PharmD, RPh; Kelly McCormick; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose. 
 
Anonymous peer reviewers are used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose. 
 
Educational Disclaimer 
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources. 
 
For questions about this internet CPE activity, please contact: 
<a href="mailto:ceinfo@pharmacytimes.com">ceinfo@pharmacytimes.com</a> 
Privacy Policy and Terms of Use Information: 
<a href="http://www.pharmacytimes.org/terms">www.pharmacytimes.org/terms</a> 
&nbsp;

Managing Multiple Sclerosis: Examining Oral Treatment Options and Specialty Pharmacy Considerations

<h2 style="text-align:center">The Evolving Treatment Landscape for Neuromyelitis Optica Spectrum Disorder: Updates for Specialty and Infusion Pharmacists&nbsp;</h2>

On-Demand 1.5-hour Accredited Webcast

<div style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px; text-align:center">This activity is supported by an educational grant from 
Genentech, a member of the Roche Group.</div>
 
Faculty Presenters 
 
Eoin P. Flanagan, MB, BCh 
Professor of Neurology 
Consultant Neurologist 
Mayo Clinic College of Medicine 
Rochester, Minnesota 
 
Erica Marini, PharmD, MS, BCPS 
Clinical Pharmacist, Neurology 
University of Utah Health 
Salt Lake City, Utah&nbsp; 
&nbsp;
<div>
<hr /></div>
 
Program Description 
Neuromyelitis optica spectrum disorder (NMOSD) is a rare disorder characterized by inflammation of the optic nerve and spinal cord that often occurs in a relapsing and remitting fashion. Diagnosis can be challenging, and many patients are misdiagnosed as having multiple sclerosis due to similarities in clinical presentation. Early diagnosis of disease and timely initiation of therapy is important as patients with NMOSD experience high rates of relapse, with neurologic deficits accumulating after each attack. Goals of therapy for patients with NMOSD include treating acute attacks and preventing relapses to diminish increasing disability. Until recently, therapy for NMOSD involved use of steroids and off-label immunosuppressants. However, recent approval of targeted biologics for the treatment of NMOSD have the potential to improve outcomes and quality of life for patients. These therapies provide new options and increased convenience for patients with NMOSD but also require special considerations for dispensing, administration, and monitoring. By incorporating the information presented in this activity, pharmacists can be involved in patient-centered care and work with the multidisciplinary team to optimize outcomes for patients with NMOSD. 
 
Target Audience:&nbsp;Managed care and specialty pharmacists 
Type of Activity:&nbsp;Application 
Release date: May 18, 2021 
Expiration date: May 18, 2022 
Time to complete activity: 1.5 hours 
Fee: Free 
 
Educational Objectives 
At the completion of this activity, participants will be able to:
<ul>
	<li>Examine the patient population afflicted with neuromyelitis optica spectrum disorder (NMOSD), including factors related to epidemiology, etiology, pathophysiology, clinical presentation, and diagnostic challenges</li>
	<li>Investigate the safety and efficacy data of new and emerging therapies for NMOSD and differentiate products based on mechanism of action</li>
	<li>Explain how specialty and infusion pharmacists can improve the care of patients with NMOSD through interventions related to medication use and education of patients and health care providers</li>
</ul>
 
<img alt="acpe" src="https://ptce.s3.amazonaws.com/_media/_eblast/ACPE_Large.jpg" style="float:left; height:59px; width:60px" />Pharmacy Times&nbsp;Continuing Education&trade; is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-21-218-H01-P. The activity is available for CE credit through May 18, 2022. 
 
 
Instructions for Completing the Activity and Receiving CPE Credit 
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date. 
&nbsp;
<hr /> 
Disclosures 
 
Eoin P. Flanagan, MBBCh, has the following relevant financial relationships with commercial interests to disclose:

<ul>
	<li>Grant/Research Support: MedImmune/Viela Bio</li>
</ul>
 
Erica Marini, PharmD, MS, BCPS, has no relevant financial relationships with commercial interests to disclose. 
 
Pharmacy Times&nbsp;Continuing Education&trade;&nbsp;Planning Staff&nbsp;&ndash; Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Rose Namissa, PharmD, BCPS; Crissy Wilson; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose. 
 
An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose. 
 
Educational Disclaimer 
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources. 
 
For questions about this internet CPE activity, please contact: 
<a href="mailto:ceinfo@pharmacytimes.com">ceinfo@pharmacytimes.com</a> 
Privacy Policy and Terms of Use Information: 
<a href="http://www.pharmacytimes.org/terms">www.pharmacytimes.org/terms</a> 
&nbsp;

The Evolving Treatment Landscape for Neuromyelitis Optica Spectrum Disorder: Updates for Specialty and Infusion Pharmacists

<h2 style="text-align:center">Interviewing the Experts in Alzheimer Disease: A Continuation of Specialist Opinion and Data</h2>

<div style="text-align:center"> 
A 1.5-hour Accredited On-Demand Virtual Symposium Presented at AMCP Annual 2021 
&nbsp;</div>

<div style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px; text-align:center">This activity is supported by an educational grant from 
Biogen Inc.</div>
 
Moderator 
Susan Trieu, PharmD 
Vice President, Trade Relations 
SPARx 
Southlake, Texas 
 
Faculty Presenters 
 
Gary Small, MD 
Chair of Psychiatry 
Hackensack University Medical Center 
 
Physician in Chief for Behavioral Health 
Hackensack Meridian Health 
Hackensack, New Jersey 
 
Winston Wong, PharmD 
President 
W-Squared Group 
Longboat Key, Florida 
&nbsp;
<div>
<hr /></div>
 
Program Description 
Before patients present with symptoms of Alzheimer disease (AD), neurons are affected due to inflammation and beta-amyloid plaques may accumulate. These plaques can often be observed with PET scans and allow for potential earlier diagnosis and therapeutic intervention. Beta-amyloid has been a focus of previous clinical trials, but research in tau antisense oligonucleotides and the protein ApoE4 in the setting of AD is expanding. Less than 5% of AD cases are considered to be the early-onset form, and early diagnosis may help improve patient quality of life and involvement in their care as well as decrease caregiver burden. To facilitate early identification of AD, managed care professionals and pharmacists must promote early identification of AD and include disease-modifying therapies into treatment protocols to preserve cognitive function in patients with AD. This interdisciplinary discussion will expand upon strategies presented at the AMCP 2020 Nexus conference that managed care professionals and pharmacists can use to collaborate to ensure guidelines for diagnosis and evaluation of AD and related dementias are incorporated into institutional management strategies. 
 
Target Audience:&nbsp;Managed care pharmacists 
Type of Activity:&nbsp;Application 
Release date: April 26, 2021 
Expiration date: April 26, 2022 
Time to complete activity: 1.5 hours 
Fee: Free 
 
Educational Objectives 
At the completion of this activity, participants will be able to:
<ul>
	<li>Examine the clinical progression of Alzheimer disease (AD) and the value of biomarkers of disease in early diagnosis as they relate to treatment selection and patient management</li>
	<li>Analyze challenges in current treatment and management strategies in AD</li>
	<li>Classify clinical data for emerging disease-modifying therapies and their importance in early identification of disease</li>
	<li>Determine future managed care strategies that will allow for the uptake of future disease-modifying therapies in AD</li>
</ul>
 
<img alt="acpe" src="https://ptce.s3.amazonaws.com/_media/_eblast/ACPE_Large.jpg" style="float:left; height:59px; width:60px" />Pharmacy Times&nbsp;Continuing Education&trade; is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-21-161-H01-P. The activity is available for CE credit through April 26, 2022. 
 
 
Instructions for Completing the Activity and Receiving CPE Credit 
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date. 
&nbsp;
<hr /> 
Disclosures 
 
Gary Small, MD, has the following relevant financial relationships with commercial interests to disclose:

<ul>
	<li>Grant/Research Support: Handok, Theravalues</li>
	<li>Consultant: Acadia, Biogen</li>
	<li>Speakers Bureau: AARP, Acadia, Biogen, Allergan, Avanir, Genentech, Gerontological Society of America, Herbalife, Lundbeck, Novartis, Otsuka, Roche, RB Health</li>
	<li>Stock/Shareholder: Ceremark Pharma</li>
</ul>
 
Susan Trieu, PharmD, and Winston Wong, PharmD, have no relevant financial relationships with commercial interests to disclose. 
 
Pharmacy Times&nbsp;Continuing Education&trade;&nbsp;Planning Staff&nbsp;&ndash; Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Dipti Desai, PharmD, CHCP; Crissy Wilson; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose. 
 
Anonymous peer reviewers are used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose. 
 
Educational Disclaimer 
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources. 
 
For questions about this internet CPE activity, please contact: 
<a href="mailto:ceinfo@pharmacytimes.com">ceinfo@pharmacytimes.com</a> 
Privacy Policy and Terms of Use Information: 
<a href="http://www.pharmacytimes.org/terms">www.pharmacytimes.org/terms</a> 
&nbsp;

Interviewing the Experts in Alzheimer Disease: A Continuation of Specialist Opinion and Data

<h2 style="text-align:center">The Foundations of Longitudinal and Adult Learning: A Continuation of Expert Opinion and Data &ndash; Interviewing the Specialists in Spinal Muscular Atrophy</h2>

<div style="text-align:center"> 
A 1.5-hour Accredited On-Demand Virtual Symposium Presented at AMCP Annual 2021 
&nbsp;</div>

<div style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px; text-align:center">This activity is supported by an educational grant from 
Biogen Inc.</div>
 
Faculty Presenters 
 
Gary M. Owens, MD 
President 
Gary Owens Associated 
Ocean View, Delaware 
 
Edmund J. Pezalla, MD, MPH 
CEO 
Enlightenment Bioconsult, LLC 
Daytona Beach, Florida 
 
Crystal M. Proud, MD 
Neuromuscular Neurologist 
Children&rsquo;s Specialty Group 
Children&rsquo;s Hospital of The King&rsquo;s Daughters 
Norfolk, Virginia 
&nbsp;
<div>
<hr /></div>
 
Program Description 
Spinal muscular atrophy (SMA) is a common fatal genetic disease and affects Caucasian populations and males at higher rates compared with African American and Hispanic populations or females. A deficiency in SMN protein causes irreversible degeneration of motor neurons, which manifests as progressive muscle weakness resulting in patients having difficulty moving, swallowing, or breathing. SMA can quickly progress to complications affecting breathing and swallowing functions, leading patients to need specialized care with ventilators and/or feeding tubes. Recently approved disease-modifying therapies and emerging treatments have the potential to change SMA treatment protocols as well as improve the quality of life for patients and caregivers. This interdisciplinary discussion will expand upon strategies presented at the AMCP 2020 Nexus conference that managed care professionals and pharmacists can use to collaborate to ensure guidelines for early diagnosis and evaluation of SMA are incorporated into institutional management strategies. 
 
Target Audience:&nbsp;Managed care pharmacists 
Type of Activity:&nbsp;Application 
Release date: April 30, 2021 
Expiration date: April 30, 2022 
Time to complete activity: 1.5 hours 
Fee: Free 
 
Educational Objectives 
At the completion of this activity, participants will be able to:
<ul>
	<li>Identify current treatment challenges in spinal muscular atrophy (SMA), burden of the disease, and the need for early intervention</li>
	<li>Analyze old and new treatment standards along with the most current data and new clinical trials that aid in the advancement of treatment protocols for patients with SMA</li>
	<li>Construct opportunities for future strategies that will allow increased access to treatment for patients with SMA</li>
</ul>
 
<img alt="acpe" src="https://ptce.s3.amazonaws.com/_media/_eblast/ACPE_Large.jpg" style="float:left; height:59px; width:60px" />Pharmacy Times&nbsp;Continuing Education&trade; is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity 0290-0000-21-171-H01-P. The activity is available for CE credit through April 30, 2022. 
 
 
Instructions for Completing the Activity and Receiving CPE Credit 
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date. 
&nbsp;
<hr /> 
Disclosures 
 
Faculty 
 
Gary M. Owens, MD,&nbsp;has the following relevant financial relationships with commercial interests to disclose:

<ul>
	<li>Consultant: Biogen, Novartis</li>
</ul>
 
Crystal M. Proud, MD,&nbsp;has the following relevant financial relationships with commercial interests to disclose:

<ul>
	<li>Grant/Research Support: AveXis, Biogen</li>
	<li>Consultant: AveXis, Biogen, Genentech</li>
	<li>Speakers Bureau: AveXis, Biogen</li>
</ul>
 
Edmund J. Pezalla, MD, MPH, has no relevant financial relationships with commercial interests to disclose. 
 
Pharmacy Times&nbsp;Continuing Education&trade;&nbsp;Planning Staff&nbsp;&ndash; Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Kim Simpson, PharmD; Crissy Wilson; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose. 
 
Anonymous peer reviewers are used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose. 
 
Educational Disclaimer 
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources. 
 
For questions about this internet CPE activity, please contact: 
<a href="mailto:ceinfo@pharmacytimes.com">ceinfo@pharmacytimes.com</a> 
Privacy Policy and Terms of Use Information: 
<a href="http://www.pharmacytimes.org/terms">www.pharmacytimes.org/terms</a> 
 
&nbsp;

The Foundations of Longitudinal and Adult Learning: A Continuation of Expert Opinion and Data - Interviewing the Specialists in Spinal Muscular Atrophy

<h2 style="text-align:center">A Breakthrough in Treatment for Dementia-Related Psychosis: A Review of Current and Future Managed Care Strategies</h2>

<div style="text-align:center"> 
A 1.5-hour Accredited On-Demand Virtual Symposium Presented at AMCP Annual 2021 
&nbsp;</div>

<div style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px; text-align:center">This activity is supported by an educational grant from 
Acadia Pharmaceuticals.</div>
 
Faculty Presenters 
 
Megan Maroney, PharmD, BCPP 
Clinical Associate Professor 
Ernest Mario School of Pharmacy at Rutgers University 
 
Clinical Psychiatric Pharmacist 
Monmouth Medical Center, RWJBarnabas Health 
Long Branch, New Jersey 
 
Alan D. Pannier, PharmD, MBA 
Head of Clinical Services 
SmithRx 
Lehi, Utah 
&nbsp;
<div>
<hr /></div>
 
Program Description 
Older adult patients with dementia-associated psychosis may experience delusions and hallucinations and exhibit agitation or aggression towards others. Current guideline recommendations for care of patients with dementia-related psychosis gives preference to nonpharmaceutical interventions, with antipsychotics reserved for use with patients experiencing severe symptoms to reduce risk of harm to themselves or others. Inappropriate use of antipsychotics for patients with dementia-related psychosis conveys safety and administration risks for older adults, which can increase direct costs to both patients and the healthcare system. Managed care professionals need to be up-to-date with clinical data associated with current and emerging therapies and should review management strategies regularly. This activity will also review the impact of dementia-related psychosis on patients and caregivers. 
 
Target Audience:&nbsp;Managed care pharmacists 
Type of Activity:&nbsp;Application 
Release date: April 27, 2021 
Expiration date: April 27, 2022 
Time to complete activity: 1.5 hours 
Fee: Free 
 
Educational Objectives 
At the completion of this activity, participants will be able to:
<ul>
	<li>Explain the clinical presentation of dementia and the high rate of psychosis in this population as well as its effect on patients and caregivers</li>
	<li>Compare existing off-label use of first- and second-generation antipsychotic medications for dementia-related psychosis, including their risks and benefits</li>
	<li>Analyze the clinical trials for the new class of drug therapy for dementia-related psychosis</li>
	<li>Optimize the role of managed care professionals in developing an evidence-based access strategy that integrates a new class of drugs for dementia-related psychosis treatment</li>
</ul>
 
<img alt="acpe" src="https://ptce.s3.amazonaws.com/_media/_eblast/ACPE_Large.jpg" style="float:left; height:59px; width:60px" />Pharmacy Times&nbsp;Continuing Education&trade; is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-21-167-H01-P. The activity is available for CE credit through April 27, 2022. 
 
 
Instructions for Completing the Activity and Receiving CPE Credit 
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date. 
&nbsp;
<hr /> 
Disclosures 
 
Megan Maroney, PharmD, BCPP, has the following relevant financial relationships with commercial interests to disclose:

<ul>
	<li>Grant/Research Support: CPNP Foundation Defining the Future research grant</li>
	<li>Consultant: Novus Medical Education</li>
	<li>Speakers Bureau: Otsuka Excel</li>
</ul>
 
Alan D. Pannier, PharmD, MBA, has no relevant financial relationships with commercial interests to disclose. 
 
 
Pharmacy Times&nbsp;Continuing Education&trade;&nbsp;Planning Staff&nbsp;&ndash; Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Crissy Wilson; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose. 
 
Anonymous peer reviewers are used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose. 
 
Educational Disclaimer 
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources. 
 
For questions about this internet CPE activity, please contact: 
<a href="mailto:ceinfo@pharmacytimes.com">ceinfo@pharmacytimes.com</a> 
Privacy Policy and Terms of Use Information: 
<a href="http://www.pharmacytimes.org/terms">www.pharmacytimes.org/terms</a> 
&nbsp;

A Breakthrough in Treatment for Dementia-Related Psychosis: A Review of Current and Future Managed Care Strategies

<h2 style="text-align:center">Current and Emerging Treatment Strategies for Cluster Seizures: A Primer for Managed Care Pharmacists</h2>

On-Demand Accredited Webinar!

<div style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px; text-align:center">This activity is supported by educational grants from 
Neurelis Inc.</div>

<div style="text-align:center">&nbsp;</div>
 
Faculty Presenter 
Kristy Greene, PharmD, BCPS, BCCCP 
Clinical Pharmacist Specialist 
Neuroscience Critical Care Medicine Emory University Hospital Midtown 
Atlanta, GA 
 
Clinical Assistant Professor 
Philadelphia College of Osteopathic Medicine, School of Pharmacy 
Suwanee, GA 
&nbsp;
<div>
<hr /></div>
 
Program Description 
 
Fifty million people worldwide have epilepsy (WHO). It is the fourth most common neurologic condition in the United States occurring in an estimated 3 million adults nationwide with approximately 150,000 new cases of epilepsy diagnosed each year. Epilepsy carries with it several social and psychological consequences. It can negatively impact an individual&#39;s ability to perform activities of daily living and consequently can affect their socioeconomic status and mental health. Epileptic seizures have a significant impact on patients&rsquo; quality of life. Cluster seizures pose a significant burden on patients with epilepsy and are characterized by multiple seizures within a short timeframe. However, this timeframe is not well defined but can consist of 2 or more seizures within a 6-24-hour window. These clusters (also referred to as acute repetitive seizures, flurries, recurrent seizures) are distinct from an epilepsy patient&rsquo;s normal seizure frequency and are more likely to occur in patients who have drug-resistant epilepsy. Ensuring that patients have access to effective rescue therapy remains a critical aspect of management. Pharmacists in managed care settings provide an important role in selecting drug therapy, monitoring, and providing education to patients. In addition, updated education about evolving treatment options, updated clinical practice guidelines, practice gaps, and emerging therapies is necessary to ensure that pharmacists are prepared to address unmet medical needs for patients and caregivers in epilepsy. 
 
Target Audience:&nbsp; Managed care pharmacists 
Type of Activity:&nbsp;Application 
Release Date: April 15, 2021 
Expiration Date: April 15, 2022 
Fee: Free 
 
Educational Objectives 
At the completion of this activity, participants will be able to:
<ul>
	<li>Examine factors that influence the classification of seizures and the burden of disease of cluster seizures</li>
	<li>Explain current and emerging rescue treatment options for patients experiencing cluster seizures</li>
	<li>Identify the role of managed care pharmacists in the development and implementation of utilization management of newer rescue treatment options for cluster seizures</li>
</ul>
 
 
<img alt="acpe" src="https://ptce.s3.amazonaws.com/_media/_eblast/ACPE_Large.jpg" style="float:left; height:59px; width:60px" />Pharmacy Times&nbsp;Continuing Education&trade; is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE 0290-0000-21-082-H01-P. The activity is available for CE credit through April 15, 2022. 
 
 
Instructions for Completing the Activity and Receiving CPE Credit 
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date. 
&nbsp;
<hr /> 
Disclosures 
 
Kristy Greene, PharmD, BCPS, BCCCP has no relevant financial relationships with commercial interests to disclose. 
 
Pharmacy Times&nbsp;Continuing Education&trade;&nbsp;Planning Staff&nbsp;&ndash; Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Dipti Desai, PharmD, CHCP; Ann Marciano; Kelly McCormick; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose. 
 
An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose. 
 
Educational Disclaimer 
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources. 
 
For questions about this live CPE activity, please contact: 
<a href="mailto:ceinfo@pharmacytimes.com">ceinfo@pharmacytimes.com</a> 
Privacy Policy and Terms of Use Information: 
<a href="http://www.pharmacytimes.org/terms">www.pharmacytimes.org/terms</a> 
&nbsp;